{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:02:59Z","timestamp":1787313779665,"version":"build-2736575974"},"reference-count":53,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1038\/mt.2016.137","type":"journal-article","created":{"date-parts":[[2016,6,30]],"date-time":"2016-06-30T07:22:14Z","timestamp":1467271334000},"page":"1435-1443","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["Adenoviral Delivery of Tumor Necrosis Factor-\u03b1 and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma"],"prefix":"10.1016","volume":"24","author":[{"given":"Mikko","family":"Siurala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riikka","family":"Havunen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipongkor","family":"Saha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dave","family":"Lumen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anu J.","family":"Airaksinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siri","family":"T\u00e4htinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00edctor","family":"Cervera-Carrascon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Bramante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suvi","family":"Parviainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"V\u00e4h\u00e4-Koskela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kanerva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akseli","family":"Hemminki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/mt.2016.137_bib1","doi-asserted-by":"crossref","first-page":"280ps7","DOI":"10.1126\/scitranslmed.aaa3643","article-title":"Adoptive cellular therapy: a race to the finish line","volume":"7","author":"June","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1038\/mt.2016.137_bib2","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1038\/mt.2016.137_bib3","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","article-title":"Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy","volume":"17","author":"Rosenberg","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1038\/mt.2016.137_bib4","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1182\/blood-2009-03-211714","article-title":"Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen","volume":"114","author":"Johnson","year":"2009","journal-title":"Blood"},{"key":"10.1038\/mt.2016.137_bib5","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1200\/JCO.2010.32.2537","article-title":"Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1","volume":"29","author":"Robbins","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1038\/mt.2016.137_bib6","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/mt.2013.17","article-title":"Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity","volume":"21","author":"Lamers","year":"2013","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2016.137_bib7","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1200\/JCO.2014.58.0225","article-title":"Human epidermal growth factor receptor 2 (HER2) -specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma","volume":"33","author":"Ahmed","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1038\/mt.2016.137_bib8","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.immuni.2013.07.002","article-title":"Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology","volume":"39","author":"Kalos","year":"2013","journal-title":"Immunity"},{"key":"10.1038\/mt.2016.137_bib9","doi-asserted-by":"crossref","first-page":"e24850","DOI":"10.4161\/onci.24850","article-title":"Trial Watch: Immunostimulatory cytokines","volume":"2","author":"Vacchelli","year":"2013","journal-title":"Oncoimmunology"},{"key":"10.1038\/mt.2016.137_bib10","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.1158\/0008-5472.CAN-09-3567","article-title":"Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients","volume":"70","author":"Cerullo","year":"2010","journal-title":"Cancer Res"},{"key":"10.1038\/mt.2016.137_bib11","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1158\/0008-5472.CAN-11-2975","article-title":"Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus","volume":"72","author":"Diaconu","year":"2012","journal-title":"Cancer Res"},{"key":"10.1038\/mt.2016.137_bib12","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1158\/1078-0432.CCR-12-2546","article-title":"Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus","volume":"19","author":"Kanerva","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1038\/mt.2016.137_bib13","doi-asserted-by":"crossref","first-page":"4467","DOI":"10.18632\/oncotarget.2901","article-title":"Immunological data from cancer patients treated with Ad5\/3-E2F-\u039424-GMCSF suggests utility for tumor immunotherapy","volume":"6","author":"Hemminki","year":"2015","journal-title":"Oncotarget"},{"key":"10.1038\/mt.2016.137_bib14","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1089\/hum.2014.069","article-title":"Immunological effects of a tumor necrosis factor alpha-armed oncolytic adenovirus","volume":"26","author":"Hirvinen","year":"2015","journal-title":"Hum Gene Ther"},{"key":"10.1038\/mt.2016.137_bib15","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00262-015-1691-7","article-title":"Adoptive T cell therapy combined with intralesional administrations of TG1042 (adenovirus expressing interferon-\u03b3) in metastatic melanoma patients","volume":"64","author":"Khammari","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"10.1038\/mt.2016.137_bib16","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1158\/2326-6066.CIR-14-0220-T","article-title":"Adenovirus improves the efficacy of adoptive T-cell therapy by recruiting immune cells to and promoting their activity at the tumor","volume":"3","author":"T\u00e4htinen","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1038\/mt.2016.137_bib17","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1634\/theoncologist.11-4-397","article-title":"TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility","volume":"11","author":"van Horssen","year":"2006","journal-title":"Oncologist"},{"key":"10.1038\/mt.2016.137_bib18","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nrc2628","article-title":"Tumour necrosis factor and cancer","volume":"9","author":"Balkwill","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1038\/mt.2016.137_bib19","doi-asserted-by":"crossref","first-page":"739","DOI":"10.18632\/oncotarget.344","article-title":"Systemic use of tumor necrosis factor alpha as an anticancer agent","volume":"2","author":"Roberts","year":"2011","journal-title":"Oncotarget"},{"key":"10.1038\/mt.2016.137_bib20","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S1470-2045(03)01141-0","article-title":"Current uses of isolated limb perfusion in the clinic and a model system for new strategies","volume":"4","author":"Eggermont","year":"2003","journal-title":"Lancet Oncol"},{"key":"10.1038\/mt.2016.137_bib21","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/sj.onc.1203251","article-title":"A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo","volume":"19","author":"Fueyo","year":"2000","journal-title":"Oncogene"},{"key":"10.1038\/mt.2016.137_bib22","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/mt.2010.161","article-title":"Treatment of cancer patients with a serotype 5\/3 chimeric oncolytic adenovirus expressing GMCSF","volume":"18","author":"Koski","year":"2010","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2016.137_bib23","doi-asserted-by":"crossref","first-page":"149185","DOI":"10.1155\/2014\/149185","article-title":"Chronic inflammation and cytokines in the tumor microenvironment","volume":"2014","author":"Landskron","year":"2014","journal-title":"J Immunol Res"},{"key":"10.1038\/mt.2016.137_bib24","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0014-5793(91)80803-B","article-title":"Tumor necrosis factor. Characterization at the molecular, cellular and in vivo level","volume":"285","author":"Fiers","year":"1991","journal-title":"FEBS Lett"},{"key":"10.1038\/mt.2016.137_bib25","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/0168-1702(89)90026-9","article-title":"Restricted replication of human adenovirus type 5 in mouse cell lines","volume":"14","author":"Blair","year":"1989","journal-title":"Virus Res"},{"key":"10.1038\/mt.2016.137_bib26","doi-asserted-by":"crossref","first-page":"5451","DOI":"10.4049\/jimmunol.1490019","article-title":"IL-2: the first effective immunotherapy for human cancer","volume":"192","author":"Rosenberg","year":"2014","journal-title":"J Immunol"},{"key":"10.1038\/mt.2016.137_bib27","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s00262-008-0455-z","article-title":"Local therapy of cancer with free IL-2","volume":"57","author":"Den Otter","year":"2008","journal-title":"Cancer Immunol Immunother"},{"key":"10.1038\/mt.2016.137_bib28","doi-asserted-by":"crossref","first-page":"8522","DOI":"10.1073\/pnas.92.18.8522","article-title":"Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model","volume":"92","author":"Addison","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/mt.2016.137_bib29","first-page":"16","article-title":"Complete recovery of mice from a pre-established tumor by direct intratumoral delivery of an adenovirus vector harboring the murine IL-2 gene","volume":"2","author":"Cordier","year":"1995","journal-title":"Gene Ther"},{"key":"10.1038\/mt.2016.137_bib30","first-page":"11","article-title":"In vivo cancer gene therapy with a recombinant interleukin-2 adenovirus vector","volume":"3","author":"Toloza","year":"1996","journal-title":"Cancer Gene Ther"},{"key":"10.1038\/mt.2016.137_bib31","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1089\/thy.1998.8.1137","article-title":"Genetic immunotherapy for medullary thyroid carcinoma: destruction of tumors in mice by in vivo delivery of adenoviral vector transducing the murine interleukin-2 gene","volume":"8","author":"Zhang","year":"1998","journal-title":"Thyroid"},{"key":"10.1038\/mt.2016.137_bib32","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/sj.gt.3300833","article-title":"Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: results of a phase 1 clinical trial","volume":"6","author":"Stewart","year":"1999","journal-title":"Gene Ther"},{"key":"10.1038\/mt.2016.137_bib33","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/mt.2008.32","article-title":"Intralesional adenovirus-mediated interleukin-2 gene transfer for advanced solid cancers and melanoma","volume":"16","author":"Dummer","year":"2008","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2016.137_bib34","first-page":"49","article-title":"Adenovirus-mediated TNF-alpha gene transfer induces significant tumor regression in mice","volume":"14","author":"Wright","year":"1999","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1038\/mt.2016.137_bib35","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1245\/ASO.2005.03.023","article-title":"TNFerade, an adenovector carrying the transgene for human tumor necrosis factor alpha, for patients with advanced solid tumors: surgical experience and long-term follow-up","volume":"12","author":"McLoughlin","year":"2005","journal-title":"Ann Surg Oncol"},{"key":"10.1038\/mt.2016.137_bib36","doi-asserted-by":"crossref","first-page":"e0131242","DOI":"10.1371\/journal.pone.0131242","article-title":"Favorable alteration of tumor microenvironment by immunomodulatory cytokines for efficient T-cell therapy in solid tumors","volume":"10","author":"T\u00e4htinen","year":"2015","journal-title":"PLoS One"},{"key":"10.1038\/mt.2016.137_bib37","first-page":"3948","article-title":"Synergistic effects of combination therapy with human recombinant interleukin-2 and tumor necrosis factor in murine tumor models","volume":"47","author":"Winkelhake","year":"1987","journal-title":"Cancer Res"},{"key":"10.1038\/mt.2016.137_bib38","first-page":"4011","article-title":"Synergistic antitumor effects of immunotherapy with recombinant interleukin-2 and recombinant tumor necrosis factor-alpha","volume":"48","author":"McIntosh","year":"1988","journal-title":"Cancer Res"},{"key":"10.1038\/mt.2016.137_bib39","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.4049\/jimmunol.1101877","article-title":"Targeting TNF-\u03b1 to neoangiogenic vessels enhances lymphocyte infiltration in tumors and increases the therapeutic potential of immunotherapy","volume":"188","author":"Calcinotto","year":"2012","journal-title":"J Immunol"},{"key":"10.1038\/mt.2016.137_bib40","doi-asserted-by":"crossref","first-page":"7841","DOI":"10.1073\/pnas.1118296109","article-title":"Tumor-targeted TNF\u03b1 stabilizes tumor vessels and enhances active immunotherapy","volume":"109","author":"Johansson","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/mt.2016.137_bib41","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/nm.4018","article-title":"Reply to Suppressive activity of human regulatory T cells is maintained in the presence of TNF","volume":"22","author":"Nie","year":"2016","journal-title":"Nat Med"},{"key":"10.1038\/mt.2016.137_bib42","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/00000421-199502000-00010","article-title":"Concomitant administration of interleukin-2 plus tumor necrosis factor in advanced non-small cell lung cancer","volume":"18","author":"Schiller","year":"1995","journal-title":"Am J Clin Oncol"},{"key":"10.1038\/mt.2016.137_bib43","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.it.2015.10.003","article-title":"Interleukin-2: Biology, Design and Application","volume":"36","author":"Arenas-Ramirez","year":"2015","journal-title":"Trends Immunol"},{"key":"10.1038\/mt.2016.137_bib44","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/imm.12037","article-title":"Local expression of interleukin-2 by B16 melanoma cells results in decreased tumour growth and long-term tumour dormancy","volume":"138","author":"Gerber","year":"2013","journal-title":"Immunology"},{"key":"10.1038\/mt.2016.137_bib45","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.4049\/jimmunol.0903009","article-title":"B cells are required for optimal CD4+ and CD8+ T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice","volume":"184","author":"DiLillo","year":"2010","journal-title":"J Immunol"},{"key":"10.1038\/mt.2016.137_bib46","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","article-title":"PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy","volume":"14","author":"Patel","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"10.1038\/mt.2016.137_bib47","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40425-016-0121-5","article-title":"Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers","volume":"4","author":"Ranki","year":"2016","journal-title":"J Immunother Cancer"},{"key":"10.1038\/mt.2016.137_bib48","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1158\/0008-5472.CAN-05-3497","article-title":"Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors","volume":"66","author":"Thomas","year":"2006","journal-title":"Cancer Res"},{"key":"10.1038\/mt.2016.137_bib49","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.1158\/0008-5472.CAN-09-3567","article-title":"Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients","volume":"70","author":"Cerullo","year":"2010","journal-title":"Cancer Res"},{"key":"10.1038\/mt.2016.137_bib50","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/ijc.28696","article-title":"Serotype chimeric oncolytic adenovirus coding for GM-CSF for treatment of sarcoma in rodents and humans","volume":"135","author":"Bramante","year":"2014","journal-title":"Int J Cancer"},{"key":"10.1038\/mt.2016.137_bib51","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1002\/ijc.29048","article-title":"Oncolytic adenovirus and doxorubicin-based chemotherapy results in synergistic antitumor activity against soft-tissue sarcoma","volume":"136","author":"Siurala","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1038\/mt.2016.137_bib52","doi-asserted-by":"crossref","first-page":"e1136046","DOI":"10.1080\/2162402X.2015.1136046","article-title":"Syngeneic Syrian hamster tumors feature tumor-infiltrating lymphocytes allowing adoptive cell therapy enhanced by oncolytic adenovirus in a replication permissive setting","volume":"5","author":"Siurala","year":"2016","journal-title":"Oncoimmunol"},{"key":"10.1038\/mt.2016.137_bib53","first-page":"275","article-title":"Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells","volume":"8","author":"Kanerva","year":"2002","journal-title":"Clin Cancer Res"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152500161633595X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152500161633595X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:50:51Z","timestamp":1761501051000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152500161633595X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":53,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["S152500161633595X"],"URL":"https:\/\/doi.org\/10.1038\/mt.2016.137","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adenoviral Delivery of Tumor Necrosis Factor-\u03b1 and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/mt.2016.137","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 American Society of Gene & Cell Therapy. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}